Astrocytomas are considered the most prevalent central nervous system tumors and originate from astrocytes.According to the WHO classification, Astrocytomas are divided into four histopathological grades based oncellular atypia, mitotic rate, vascular changes, and necrosis.1 Proper astrocytoma grading helps neurosurgeonsand neuro-oncologists treat and assess the overall prognosis properly. Numerous studies have relied on variousfactors, ranging from tumor suppressor genes to proliferation markers, to gain insights into tumor behavior.Ki-67 and p53 are two cellular proteins that have roles in the pathogenesis and progression of astrocytoma.Ki-67 is a nuclear non-histone protein antigen expressed at the cell cycle’s G1, S, G2, and M phases and absentin the resting cells (G0). The monoclonal antibody MIB-1 detects Ki-67 nuclear antigens in proliferating cells,and the percentage of immunopositive cells is referred to as the Ki-67 labeling index (LI). The Ki-67 labelingindex (proliferative index) estimates the growth of neoplasms quantitatively and can act as an ancillary tool inunderstanding tumor behavior. The product of the normal TP53 gene is a nuclear phosphoprotein known as p53(“wild type” p53 protein). It is one of the major factors governing cell proliferation, suppressing growth, and celltransformation. Mutations result in the alteration of the p53 protein, and this “mutant” protein, having a longerhalf-life than the “wild protein,” aggregates in the nucleus, reacting at a threshold of immunohistochemicaldetection